NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Borgen, Elin; Rypdal, Maria C.; Sosa, Maria Soledad; Renolen, Anne; Schlichting, Ellen; Lønning, Per E.; Synnestvedt, Marit; Aguirre-Ghiso, Julio A.; Naume, Bjørn

doi:10.1186/s13058-018-1049-0

Breast Cancer Research

Table 1 Overview of all originally disseminated tumor cell (DTC)-positive patients with detectable DTCs by double immunofluorescence technique and clinicopathological parameters

From: NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Patient identifier	Study	BMA time points^a	NR2F1/AE1AE3 DIF analysis		Ki67/AE1AE3 DIF analysis		HR	HER2	T status	N status	Time (months) from BMA to systemic relapse or BC death	Relapse status or BC death (if not recorded relapse)	Time (months) from BMA to last observation if no relapse	Comment
Patient identifier	Study	BMA time points^a	No. of DTCs	% NR2F1^high DTCs	No. of DTCs	% Ki67+ DTCs	HR	HER2	T status	N status	Time (months) from BMA to systemic relapse or BC death	Relapse status or BC death (if not recorded relapse)	Time (months) from BMA to last observation if no relapse	Comment
20	N	(BM1)-BM3	35	0	7	28.6	pos	nd	3	2	0.30	Bone and visceral
74	S	(BM1-BM3)-BM4	3	0	nd	nd	pos	neg	1	1	1.09	Bone
5	O	(BM1)/BM2	1000	0	1000	15.0	pos	pos	1	1	1.15	Bone
60	S	(BM2)-BM3	1000	0^b	84	26,2	pos	neg	2	1	1.84	Bone
27	N	(BM1)-BM2	5	0^c	nd	nd	neg	nd	3	0	5.69	Visceral
62	S	BM2	40,000	0	nd	nd	pos	neg	2	0	5.79	Bone and visceral		Chemo after BMA
4	O	(BM1)-BM2	9	0	23	21.7	pos	neg	3	1	7.50	Bone and visceral
3	O	BM1	11	0	nd	nd	pos	neg	2	1	11.22	Visceral
78	S	(BM1)-BM2-(BM3)	26	0	29	13.8	pos	neg	2	3	13.19	Bone and visceral		Chemo after BMA
13	O	BM1	79	0	nd	Nd	neg	pos	1	1	13.22	Bone		Chemo after BMA
17	N	BM3	5	0	4	25.0	pos	nd	3	1	17.57	Bone and visceral
34	N	BM1-(BM2)	2	0	nd	nd	pos	neg	3	1	47.43	Visceral		Chemo after BMA
12	O	BM2	16	0	nd	nd	pos	neg	2	1		No relapse	57.73
66	S	BM1-(BM4)	3	0	nd	nd	pos	neg	1	2		No relapse	87.50	Chemo after BMA
11	O	(BM1)-BM2	500	1.0	87	66.7	neg	pos	3	1	3.72	BC death
23	N	BM3	50	10.0	16	12.5	pos	pos	3	0	13.55	BC death
35	N	(BM1)-BM3	7	14.3	12	25.0	pos	nd	3	2	N/A	^d		Met. before BMA
48		(BM1)-BM3	17	25.5	10	20.0	pos	nd	3	0	12.24	Bone
41	N	BM3	111	30.6	82	17.1	pos	nd	4	1	N/A	^d		Met. before BMA
36	N	(BM1)-BM3	6	50,0	4	50.0	pos	nd	3	1	25.33	Bone
84	S	(BM1)-BM2	2	50.0	nd	nd	pos	neg	2	2		No relapse	55.53	Chemo after BMA
9	O	BM1	48	56.3	nd	Nd	neg	neg	2	1	N/A	Bone^d		Met. at BMA
85	S	(BM1)-BM2	106	56.6	70	10.0	pos	neg	2	2		No relapse	56.02	Chemo after BMA
69	S	(BM1)-BM2-(BM3)	52	65.4	35	0	pos	neg	2	2	15.10	Visceral		Chemo after BMA
6	O	(BM1)-BM2	233	94.9	400	1.0	neg	pos	1	1	N/A	Visceral		Met. before BMA
57	S	(BM3)-BM4	6	100	nd	nd	neg	nd	2	0		No relapse	59.93

BC breast cancer, Chemo chemotherapy, DIF double immunofluorescence, HR hormone receptor, Met. metastasis, N Neotax, N/A not applicable, nd not determined, neg negative, O Oslo1, pos positive, S SATT
^aThe bone marrow aspiration (BMA) time points for each patient are noted. In this table, the DTC results are only presented for the BMAs highlighted in bold (last positive sample); results from the other BMA time points are available in Additional file 1 (Table S1) and partly in Fig 3
^bIn the first bone marrow (BM) sample, 46.3% of the DTCs were NR2F1^high
^cIn the first BM sample, 33.3% of the DTCs were NR2F1^high
^dMetastasis before BMA

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com